Cost‐effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper‐limb post‐stroke spasticity in <scp>S</scp>cotland

Abstract

Based on a model, UC plus onabotulinumtoxinA improved disability, which translated into greater QALYs but also increased direct medical costs compared with UC alone; however, the resulting ICER can be considered cost-effective. Moreover, UC plus onabotulinumtoxinA can be cost-saving if reduction in caregiver burden was included. OnabotulinumtoxinA offers value for money in the management of ULPSS in Scotland.